Cancer & Disease Research
How one cell transplant platform is poised to tackle complex diseases
Lineage Cell Therapeutics CEO Brian Culley discusses the company's cell therapy technology with ScienceBoard.net. The technology involves the transplantation of differentiated stem cells as part of an off-the-shelf allogeneic cell therapy. Read More
AACR 2021: A case study of T-cell modulation for cancer immunotherapies
During a plenary session at the American Association for Cancer Research (AACR) 2021 virtual meeting held April 9-14, speakers described impressive work that researchers have done to modify and target T cells as a means of treating cancers. Read More
A CRISPR on-off switch for genes controls expression without altering DNA
A new gene silencing tool allows scientists to switch genes on and off without altering genetic sequences. The tool, described in a paper published in Cell on April 9, uses a modified CRISPR-Cas9 system to introduce reversible epigenetic changes that control gene expression. Read More
2nd-gen stem cell-derived CAR gene therapy is more durable, effective against HIV
A novel second-generation chimeric antigen receptor (CAR)-based approach targeting HIV infection using the genetic modification of hematopoietic stem cells shows promise in preclinical models. The details of the study were published in PLOS Pathogens on April 1. Read More
Scientists develop ultraspecific CAR T cells that kill only cancer cells
Scientists have devised a two-step engineering circuit that precisely targets solid tumors with chimeric antigen receptor (CAR) T cells. The engineering feat could be the next step in treating solid tumors using therapeutic T cells, a treatment that has remained out of reach for many cancer patients. The new method was detailed in a Science article on March 12. Read More
Preclinical lung imaging offers effective evaluation of drug candidates
Drug discovery and development are arduous and costly endeavors, with nine in 10 drug candidates failing to gain approval. Preclinical imaging can help pharmaceutical companies more effectively evaluate drug candidates, in particular for respiratory diseases. Read More
Dual-antigen CAR T system could be effective at treating solid tumors in children
A new chimeric antigen receptor (CAR) T-cell system that targets two tumor antigens may be effective at treating difficult solid tumors in children in cases where other CAR T therapies have not been effective. Findings from the preclinical evaluation of the novel CAR system were published in Nature Communications on January 21. Read More
What makes immuno-oncology therapies attractive investments?
Although immuno-oncology therapies have been around for many years, investors are excited to partner with innovators in the space who can push the boundaries of what these therapies are able to achieve. A panel of investors and business development executives discussed what exactly makes a specific candidate attractive as a business opportunity during a recorded session at the Biotech Showcase virtual event. Read More
Tackling the next hurdle in cell and gene therapy: Manufacturing
Although innovation continues to occur at lightning fast speeds in the cell and gene therapy space, commercialization and manufacturing of these technologies is still playing catch-up. A group of investors and executives from across the industry discussed this issue in an on-demand session of the Biotech Showcase virtual event. Read More
Regulatory Roundup: Designations come through before year's end
This week's Regulatory Roundup covers activities from November 30 to December 4 and is filled with breakthrough, orphan, and rare disease designations from the U.S. Food and Drug Administration and the European Medicines Agency. Several cancer, immunotherapy, and vaccine companies also submitted biologic license applications to move their candidates forward. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter